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Abstract
Background: Instrumental variable analysis, for example with physicians’ prescribing
preferences as an instrument for medications issued in primary care, is an increasingly
popular method in the field of pharmacoepidemiology. Existing power calculators for
studies using instrumental variable analysis, such as Mendelian randomization power
calculators, do not allow for the structure of research questions in this field. This is be-
cause the analysis in pharmacoepidemiology will typically have stronger instruments
and detect larger causal effects than in other fields. Consequently, there is a need for
dedicated power calculators for pharmacoepidemiological research.
Methods and Results: The formula for calculating the power of a study using instrumen-
tal variable analysis in the context of pharmacoepidemiology is derived before being
validated by a simulation study. The formula is applicable for studies using a single bin-
ary instrument to analyse the causal effect of a binary exposure on a continuous out-
come. An online calculator, as well as packages in both R and Stata, are provided for the
implementation of the formula by others.
Conclusions: The statistical power of instrumental variable analysis in pharmacoepide-
miological studies to detect a clinically meaningful treatment effect is an important
consideration. Research questions in this field have distinct structures that must be
accounted for when calculating power. The formula presented differs from existing in-
strumental variable power formulae due to its parametrization, which is designed specif-
ically for ease of use by pharmacoepidemiologists.
Key words: Pharmacoepidemiology, instrumental variable, power, binary exposure, continuous outcome, prescrib-
ing preference
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Introduction
Pharmacoepidemiological studies risk irrelevance if they
are insufficiently powered to detect clinically meaningful
treatment effects. Before starting a study, the statistical
power to calculate a given treatment effect can be calcu-
lated. This type of calculation is becoming increasingly im-
portant for grant and data request applications, which
look to value the contribution of such studies.
The number of pharmacoepidemiology studies using in-
strumental variable analysis, for example with physicians’
prescribing preferences as an instrument for exposure, con-
tinues to grow.1–6 This is partly because instrumental vari-
able analyses have the potential to overcome some of the
issues associated with conventional statistical approaches,
such as residual confounding and reverse causation. As the
demand to provide power calculations to support applica-
tions increases, there is a more pressing need to be able to
provide power calculations for this method.
There are power calculators for instrumental variable
analysis in other settings, such as Mendelian randomiza-
tion, which uses germline genetic variants as proxies for
exposures in disease-related research.7,8 However, phar-
macoepidemiological research questions have distinct
structures that are not sufficiently catered for by these
existing calculators. Unlike Mendelian randomization
studies, which often use a case-control study design, phar-
macoepidemiology studies typically use a cohort study de-
sign. Further to this, pharmacoepidemiology studies
usually report a risk difference for a binary exposure using
a binary instrument, whereas Mendelian randomization
studies report on a continuous exposure using a discrete or
continuous genetic instrument (count of alleles or allele
score respectively). As a result of these differences, as well
as the stronger instruments and larger causal effects seen in
pharmacoepidemiology, there is a need for a dedicated
power calculator for instrumental variable analysis in the
context of this field.
This paper will address how to conduct power calcula-
tions for pharmacoepidemiological studies using a single
binary instrument to analyse the causal effect of a binary
exposure on a continuous outcome. The formula to calcu-
late power will be derived and then validated by a simula-
tion study. The formula is distinct from existing
instrumental variable power formulae due to its paramet-
rization, which is designed specifically for ease of use by
pharmacoepidemiologists. An online calculator, as well as
packages in both R and Stata, are provided for the imple-
mentation of the formula by others.
Methods and Results
Let us consider physicians’ prescribing preferences for two
different treatments–for example a treatment of interest
and a control treatment–as an instrument for exposure to
these treatments. Physicians’ preferences are generally not
directly observable, so each physician’s prescriptions to
previous patients are used as a proxy for their preferences.
This results in a binary instrument that takes a value of
one if the physician issued a prescription for the treatment
of interest to their previous patient and a value of zero if
they prescribed the control treatment. We will derive the
formula for the power of studies that use this instrument to
measure the causal effect of a drug exposure on a continu-
ous outcome, for example systolic blood pressure or low-
density lipoprotein cholesterol.
Formula derivation
The instrumental variable analysis we consider requires the
following three variables; namely a binary instrument Z, a
binary exposure X and a continuous outcome Y. The out-
come for patient i, for i ¼ 1; . . . ;n, is modelled as follows:
Yi ¼ aþ bXi þUi
where Ui is a zero-mean error term containing unobserved
confounders, determining both the outcome Yi and the
treatment Xi. The instrument Zi affects treatment Xi, but
is not associated with the unobserved confounders and has
no direct effect on the outcome.
Key Messages
• Research questions using instrumental variable analysis in pharmacoepidemiology have distinct structures that have
previously not been catered for by instrumental variable analysis power calculators.
• Power can be calculated for studies using a single binary instrument to analyse the causal effect of a binary exposure
on a continuous outcome in the context of pharmacoepidemiology using the presented formula, an online power cal-
culator or packages available for use in both R and Stata.
• The use of this power calculator will allow investigators to determine whether a pharmacoepidemiology study is
likely to detect clinically meaningful treatment effects before the study’s commencement.
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Let ~Yi ¼ Yi  Y , ~Xi ¼ Xi X and ~Zi ¼ Zi  Z, where
Y , X and Z are sample averages. Denote by ~y, ~x and ~z
the n-vectors of observations on ~Yi, ~Xi and ~Zi, respectively.
The two-stage least squares (2SLS) estimator of b is then
given by:
b^ ¼ ð~z0~xÞ1~z0~y:
The variance of the 2SLS estimator is:
Varðb^Þ ¼ r2ð~x0P~z ~xÞ1
where P~z ¼ ~zð~z0~zÞ1~z0 and r2 ¼ EðU2i Þ is the residual vari-
ance. Note that conditional homoscedasticity holds, so the
variance is constant for all values of the instrument i.e.
EðU2i Þ ¼ EðU2i jZiÞ ¼ r2 for i ¼ 1; . . . ; n.
Consider the term ~x0P~z ~x:
~x0P~z ~x ¼ ~x0~zð~z0~zÞ1~z0~x ¼ n ~x
0~z
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Let pZ ¼ PðZ ¼ 1Þ, pX ¼ PðX ¼ 1Þ and pXZ ¼ PðX ¼
1jZ ¼ 1Þ. In large samples:
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Hence ~x0P~z ~x can be presented in the following way:
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Now consider the instrumental variable estimator of b.
Using the asymptotic distribution b^  N

b;r2ð~x0P~z ~xÞ1

,
the distribution of the t-test statistic under the null hypoth-
esis H0 : b ¼ b0 is:
t ¼ b^  b0
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The distribution of the test statistic under the alternative
hypothesis H1 : b ¼ b0 þ d is:
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The null hypothesis is rejected if jtj > ca where ca is the
critical value at significance level a.
The power is the probability that the test statistic will
exceed the critical value, which is:
Pðt > caÞ þ Pðt < caÞ ¼ U ca þ d
r
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where UðsÞ is the cumulative standard normal distribution
function evaluated at s. Power therefore increases as the
value of r decreases and/or the value of ~x0P~z ~x increases. By
substituting ~x0P~z ~x and simplifying, we obtain the follow-
ing formula for power:
Power ¼ U ca þ
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The formula requires a total of seven parameters to be
specified. This includes four parameters that must always
be specified–these are the significance level, a; the size of
the causal effect, d; the residual variance, r2 ¼ EðU2i Þ; and
the sample size, n. Also three that can be chosen from the
following four parameters–these are the frequency of the
instrument, pZ ¼ PðZ ¼ 1Þ; the frequency of exposure,
pX ¼ PðX ¼ 1Þ; the probability of exposure given the
instrument Z ¼ 1, pXZ ¼ PðX ¼ 1jZ ¼ 1Þ; and the
probability of exposure given the instrument Z ¼ 0,
pXZ ¼ PðX ¼ 1jZ ¼ 0Þ. The chosen parameters must be
specified so that the following holds:
PðX ¼ 1Þ ¼ PðX ¼ 1jZ ¼ 0ÞPðZ ¼ 0Þ þ PðX ¼ 1jZ ¼ 1ÞPðZ ¼ 1Þ
The formula for power is available for use via an online
calculator [https://venexia.shinyapps.io/PharmIV/] and
packages for R and Stata can be downloaded from GitHub
[https://github.com/venexia/PharmIV].
Note that the frequency of exposure in an instrumental
variable analysis of this type is likely to be higher than in a
general population study because a drug is compared
against one or more other drugs in a population of people
with the indication for these treatments. General popula-
tion studies, on the other hand, tend to compare a popula-
tion who received the drug of interest with a population
who did not receive it, and consequently the frequency of
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exposure is generally much lower. The effect of varying the
parameters within the formula on a study’s power is best
presented graphically. Figure 1 illustrates an example of
the effect of the frequency of the exposure pX ¼ PðX ¼ 1Þ
on the power of a study to detect a causal effect of d ¼ 
0:150 using an instrument with a frequency of pZ ¼ 0:200,
a residual variance of r2 ¼ 1 and a sample size of up to
30 000 participants. Both increasing the frequency of ex-
posure up to 50% and increasing the sample size results in
increased power for this study.
Formula validation
To validate the power formula, we conducted a simulation.
We simulated the data by defining the three variables ne-
cessary to conduct instrumental variable analysis with a
single instrumental variable as follows:
Instrument : Zi  Binomialð1;pZÞ
Exposure : Xi 
(
0; if c0 þ Ziðc1  c0Þ þ Vi 0
1; if c0 þ Ziðc1  c0Þ þ Vi > 0
Outcome : Yi  dXi þUi
where pZ ¼ PðZ ¼ 1Þ is the frequency of the instrument,
cj ¼ A1

PðX ¼ 1jZ ¼ jÞ

for j ¼ 0; 1 are the inverse
cumulative standard normal distribution, or quantile, func-
tions of the conditional probabilities of exposure given the
instrument, d is the causal effect, and Ui and Vi are stand-
ard normally distributed error terms with covariance q.
The formula uses a binary instrument, binary exposure
and continuous outcome and so the above variables were
simulated to recreate data of this form. The instrument Z
is modelled by a binomial distribution parameterized by its
frequency pZ ¼ PðZ ¼ 1Þ. This ensures a binary variable
with the correct probability of success. The exposure X is
also binary but is modelled using a threshold model. The
variability in the equation for the exposure comes from the
normally distributed error term Vi. The use of the model
equation allows the exposure X to be associated with the
instrument Z. The outcome Y is modelled by its model
equation Yi ¼ dXi þUi. In the model, the instrument is
valid as the outcome Y is only associated with the exposure
X; as dictated by the causal effect d, and is not associated
with the instrument Z other than through the exposure X.
Using the generated data, we performed an instrumental
variable analysis using the command IVREG2 in Stata.9
From this analysis, we recorded the coefficient of the ex-
posure X with the 95% confidence interval. We then
counted the number of simulations for which the confi-
dence interval excluded the null, and divided this by the
total number of simulations to determine the power. By
running the simulation and calculating the formula using
the same parameters, we are able to validate the formula
against the simulation.
We present the power calculated from both the simula-
tion and the formula for several parameter combinations
in Table 1. The table contains 27 different simulations
and each was repeated 10 000 times. The simulations con-
sider each combination of three values of the frequency
of exposure, pX ¼ 0:100;0:250; 0:500; three values of the
probability of exposure given the instrument Z ¼ 1,
pXZ ¼ 0:150;0:300; 0:450; and three values of the sam-
ple size, N ¼ 10000;20000;30000. We set the frequency
of the instrument, pZ ¼ 0:200; the causal effect,
d ¼ 0:150; the residual variance, r2 ¼ 1; and calculated
PðX ¼ 1jZ ¼ 0Þ according to the following equation:
PðX ¼ 1jZ ¼ 0Þ ¼ PðX ¼ 1Þ  PðX ¼ 1jZ ¼ 1ÞPðZ ¼ 1Þ
1  PðZ ¼ 1Þ
¼ pX  pXZpZ
1 pZ
The effect of confounding was removed as a parameter be-
cause the power was insensitive to its value in the simula-
tion setting. Details of the simulations conducted to test
this can be found in Supplementary File 1, available as
Supplementary data at IJE online. The Stata code for this
paper, including that used to create the simulation, is avail-
able from GitHub [https://github.com/venexia/PharmIV].
Simulation results
The formula and the simulation consistently provide simi-
lar results, with an absolute mean difference of 0:4% for
Figure 1. Power curves for several values of the frequency of exposure
pX ¼ P ðX ¼ 1Þ that show the effect on the power of a study to detect a
causal effect of d ¼ 0:150 using an instrument with a frequency of
pZ ¼ 0:200, a residual variance of r2 ¼ 1 and a sample size of up to
30 000 participants.
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the parameter combinations presented in Table 1. There is
also no discernible pattern in the differences, suggesting
systematic bias is not present. Further to this, the power is
consistent with its behaviour in other established power
calculations. For example, increasing sample size univer-
sally improves power for all parameter combinations.
Discussion
In this paper, we have derived the formula necessary to cal-
culate power for instrumental variable analysis with a single
binary instrument, binary exposure and continuous out-
come in the context of pharmacoepidemiology. The formula
has been shown to be valid by comparison against a simula-
tion study, which concluded that the formula provided near
true values across a range of realistic parameters.
We acknowledge that there is some overlap of this cal-
culator with existing calculators such as that proposed by
Burgess for Mendelian randomization.7 Although both cal-
culators ultimately have a shared aim, namely to calculate
the power of a study using an instrumental variable ana-
lysis, their application makes the calculators distinct. This
is evident from the choice of parameterization of the power
formula. The Mendelian randomization calculator opts for
the coefficient of determination, R2. This is a natural
choice for the application, as it summarizes the proportion
of the variance expected to be explained by genetic factors.
In contrast, we have opted to parameterize our calculator
for use in pharmacoepidemiological studies in terms of the
frequency of the instrument, the frequency of the exposure
and the conditional probabilities that relate them. This is
more intuitive to a pharmacoepidemiological audience
who will typically use the proportion of patients exposed,
i.e. the frequency of exposure. In addition to this, the in-
struments typically used in this framework–for example,
physicians’ prescribing preference–do not necessarily fit as
naturally to the notion of variance explained and are
summarized much more easily by their frequency and their
relationship with exposure.
A concern for any instrumental variable analysis,
whether in the context of pharmacoepidemiology or not, is
the strength of the instrument. Instruments are termed weak
when the correlation between the instruments and the
exposure is low.10 A commonly cited threshold is a partial F
statistic of the association between the instrument and the
exposure of less than 10.8,11 Weak instruments will result in
low power to detect a causal effect.12–14 They are also
known to induce bias, as such instruments may explain only
a small proportion of the association between the exposure
and outcome. Therefore, although pharmacoepidemiologi-
cal studies are likely to have stronger instruments than other
forms of instrumental variable analysis such as Mendelian
randomization, researchers should remain mindful of their
choice of instrument and whether it is appropriate for the
research question they wish to study.
As for any power formula, the formula presented here is
limited by its parameters, which simplify the dataset being
considered. Power calculated from such formulae cannot
account for dataset characteristics outside these param-
eters. For example, the formula makes no allowance for
the presence of missing data–a known limiting factor in the
power of a study. By allowing for missing data in the
anticipated sample size, conservative estimates for the
power of a study can be obtained using the formula pre-
sented. Further work is needed in order to establish the for-
mula for power in other scenarios that use instrumental
variable analysis within a pharmacoepidemiology context.
This includes analyses with binary outcomes and analyses
that involve multiple instrumental variables.
As the use of instrumental variable analysis in pharma-
coepidemiology becomes more commonplace, there is an
increasing need to provide power calculations for studies
using this type of analysis. To provide such information,
accessible and accurate power formulae need to be made
Table 1. A comparison of the power calculated from the formula and a validation simulation for an instrumental variable ana-
lysis where the causal effect d ¼ 0:150, the frequency of the instrument pZ ¼ 0:200 and the residual variance r2 ¼ 1
pX pXZ 10 000 patients 20 000 patients 30 000 patients
Formula Simulation Formula Simulation Formula Simulation
0.100 0.150 6.6% 6.1% 8.3% 7.9% 10.0% 9.8%
0.300 32.3% 33.3% 56.4% 55.5% 73.8% 73.9%
0.450 74.7% 75.6% 96.0% 95.9% 99.5% 99.5%
0.250 0.150 11.7% 11.4% 18.6% 18.3% 25.5% 25.5%
0.300 6.6% 5.4% 8.3% 7.9% 10.0% 9.8%
0.450 32.3% 32.8% 56.4% 56.1% 73.8% 73.7%
0.500 0.150 74.7% 74.2% 96.0% 95.9% 99.5% 99.6%
0.300 32.3% 32.5% 56.4% 57.1% 73.8% 73.7%
0.450 6.6% 5.0% 8.3% 7.2% 10.0% 10.1%
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available. By using the formula presented here, either dir-
ectly or via the online tool and packages in R and Stata, it
is hoped that pharmacoepidemiologists can calculate the
power of instrumental variable analysis studies with a sin-
gle binary instrument, binary exposure and continuous
outcome with ease.
Supplementary Data
Supplementary data area available at IJE online.
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